ERBB2 and breast carcinoma: The antitumor efficiency was validated in nude mice implanted with human HER2‐positive breast cancer cells.[9e] Without the loading of additional therapeutic agents, the HER2‐binding nanoMIP significantly inhibited tumor growth without showing obvious biological toxicity compared to control groups.[9e]